Genovis: Adding genomics exposure - Redeye

Redeye comments on Genovis’ decision to acquire the remaining 75% of SEQURNA, viewing it as a logical, synergistic move that leverages its growing net cash and adds exposure to the sizable and growing genomics market.

Länk till analysen i sin helhet: https://www.redeye.se/research/1116656/genovis-adding-genomics-exposure?utm_source=finwire&utm_medium=RSS